

## **Abstract: PB2918**

### **Title: DESENSITIZATION TO BRENTUXIMAB VEDOTIN AFTER ANAPHYLAXIS IN HODGKIN'S LYMPHOMA**

**Abstract Type: Publication Only**

**Topic: Hodgkin lymphoma - Clinical**

#### **Background:**

Rapid drug desensitization is a procedure designed to temporarily induce tolerance to the drug in patients who have experienced hypersensitivity reactions. In this instance, we report a desensitization regimen with Brentuximab Vedotin

#### **Aims:**

In this instance, we report a desensitization regimen with Brentuximab Vedotin .

#### **Methods:**

We conducted an analysis on patients with hypersensitivity reactions among Hodgkin lymphoma patients treated with Brentuximab from January 2021 to December 2023.

#### **Results:**

The hypersensitivity reaction incidence was 4.5% (2 patients among 44) . We present two cases of advanced stage IV Hodgkin's lymphoma, refractory to three lines of therapy, requiring salvage treatment with the Bendamustine-Brentuximab Vedotin combination. An infusion-related reaction (grade 3 and grade 4 anaphylaxis to BV administration) occurred in cycle 2, prompting temporary treatment discontinuation.

To resume Brentuximab Vedotin, a 12-steps desensitization protocol was employed. Following premedication with antihistamines methylprednisolone and paracetamol, a total BV dose (1.8 mg/kg) was administered in three infusions with progressively increasing rate and concentration : the first infusion included 0.05 mg of Brentuximab, the second had 0.95 mg of the drug, and the third contained the remaining dose. The duration of infusion was 6 hours. Hospitalization was needed at every cycle for 48 hours.

The protocol proved successful, enabling subsequent infusions during subsequent cycles without hypersensitivity reactions

#### **Summary/Conclusion:**

Considering the absence of many therapeutic alternatives in our country and the pivotal role of Brentuximab in Hodgkin's lymphoma treatment, anaphylaxis to Brentuximab will not deprive the patient of treatment, thanks to desensitization, which is a viable approach . This protocol may find broader applicability in addressing hypersensitivity reactions associated with other monoclonal antibodies .

**Keywords:** Treatment, Hodgkin's lymphoma